1. Home
  2. ROIV vs ICL Comparison

ROIV vs ICL Comparison

Compare ROIV & ICL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ROIV
  • ICL
  • Stock Information
  • Founded
  • ROIV 2014
  • ICL 1968
  • Country
  • ROIV United Kingdom
  • ICL Israel
  • Employees
  • ROIV N/A
  • ICL 13067
  • Industry
  • ROIV Biotechnology: Pharmaceutical Preparations
  • ICL Agricultural Chemicals
  • Sector
  • ROIV Health Care
  • ICL Industrials
  • Exchange
  • ROIV Nasdaq
  • ICL Nasdaq
  • Market Cap
  • ROIV 8.4B
  • ICL 8.8B
  • IPO Year
  • ROIV N/A
  • ICL N/A
  • Fundamental
  • Price
  • ROIV $10.79
  • ICL $6.74
  • Analyst Decision
  • ROIV Buy
  • ICL Hold
  • Analyst Count
  • ROIV 4
  • ICL 2
  • Target Price
  • ROIV $17.50
  • ICL $6.75
  • AVG Volume (30 Days)
  • ROIV 5.9M
  • ICL 685.0K
  • Earning Date
  • ROIV 05-29-2025
  • ICL 05-19-2025
  • Dividend Yield
  • ROIV N/A
  • ICL 2.78%
  • EPS Growth
  • ROIV N/A
  • ICL N/A
  • EPS
  • ROIV N/A
  • ICL 0.32
  • Revenue
  • ROIV $122,585,000.00
  • ICL $6,841,000,000.00
  • Revenue This Year
  • ROIV N/A
  • ICL $4.71
  • Revenue Next Year
  • ROIV N/A
  • ICL $4.08
  • P/E Ratio
  • ROIV N/A
  • ICL $21.49
  • Revenue Growth
  • ROIV 140.04
  • ICL N/A
  • 52 Week Low
  • ROIV $8.73
  • ICL $3.79
  • 52 Week High
  • ROIV $13.06
  • ICL $6.84
  • Technical
  • Relative Strength Index (RSI)
  • ROIV 50.06
  • ICL 59.22
  • Support Level
  • ROIV $10.58
  • ICL $6.68
  • Resistance Level
  • ROIV $11.77
  • ICL $6.89
  • Average True Range (ATR)
  • ROIV 0.34
  • ICL 0.11
  • MACD
  • ROIV -0.07
  • ICL -0.03
  • Stochastic Oscillator
  • ROIV 17.65
  • ICL 49.88

About ROIV Roivant Sciences Ltd.

Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

About ICL ICL Group Ltd.

ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and growing solutions. These segments all contribute to the company's development of agriculture, food, and engineered material products and services. Maximum revenue is generated from its phosphate solutions segment which uses phosphate commodity products, such as phosphate rock and fertilizer-grade phosphoric acid (green phosphoric acid), to produce specialty products. This segment also produces and markets phosphate-based fertilizers. Geographically, the company generates maximum revenue from Brazil followed by, the United States of America, China, United Kingdom, Germany, Spain, Israel, France, India, Netherlands, and other countries.

Share on Social Networks: